INTRODUCTION
The tumor-associated antigen MUC-1, or MUC-1/DF-3, is overexpressed on the cell surface of many human adenocarcinomas, such as ovarian, breast, pancreatic, colorectal, and prostate carcinoma, and in hematological malignancies, including multiple myeloma and some B-cell non-Hodgkin lymphomas (1) (2) (3) (4) (5) . Although MUC-1 is expressed on some normal epithelial tissue on lumenal surfaces, it has been demonstrated that the apical localization of MUC-1 is lost in tumor tissues. In addition, MUC-1 is underglycosylated in human adenocarcinomas as compared with normal tissues, and, thus, the antigenic epitopes of the protein core are more exposed (6) . A high level of MUC-1 expression and secretion has also been shown to be associated with poor prognosis and high metastatic potential (7) (8) (9) (10) . It was initially demonstrated that MHC-unrestricted cytotoxic T cells could be established from patients with pancreatic carcinoma (11) , ovarian cancer (12) , and multiple myeloma (13, 14) ; these T cells were shown to recognize the MUC-1 protein core in the 20-amino-acid (15, 16) variable number of tandem repeat (VNTR) region. More recently, it has been demonstrated that MHC-restricted T cells that recognize epitopes in the VNTR region could also be induced (17, 18) . It has also been reported that CTLs could be generated to MUC-1 peptides in HLA-A2/K b transgenic mice immunized with mannan-mucin (MUC-1) fusion protein containing five repeats of the 20-amino acid VNTR (19) . Peptides within the VNTR have been studied by many investigators because VNTR is the most immunogenic region in MUC-1 when the whole cancer cells or mucin extracts are used to immunize hosts for the production of antibodies. Although the VNTR region is immunogenic for MHC unrestricted CTLs as well as for the production of MUC-1 specific antibodies (11, 17, 20) , relatively limited information is available with respect to the immunogenicity of the region outside the VNTR.
Potential CTL epitope sequences outside the VNTR have now been identified (21) (22) (23) (24) . Two 9-mer MUC-1 peptides (STAPPVHNV, amino acid 950 -958, and STAPPAHGV, amino acid 130 -138), which are located outside the VNTR region and which can induce HLA-A2-restricted human CTLs in vitro, have been identified (21) . It has also been demonstrated that CTLs can be generated in BALB/c, C57BL/6, HLA-A0201/ K b , and double transgenic HLA-A0201/K b ϫ human MUC-1 (A2KbMUC-1) mice by immunization with human milk fat membrane antigen (22) . A 9-mer peptide (amino acid 12-20, LLLLTVLTV) derived from the leader sequence of the MUC-1 protein has also been identified for its ability to bind to the HLA-A2 molecule and may be a potential CTL epitope for MUC-1-specific CTLs. The fact that MUC-1 is overexpressed and underglycosylated in tumor versus normal tissue, and that MHC-restricted and MHC-unrestricted human CTLs could be generated, which, in turn, was shown to lyse MUC-1-positive tumor cells, suggests that MUC-1 is a potential target for immunotherapy of many cancer types.
It has been demonstrated that one way to modify the immunogenicity of a peptide of a self-antigen is to alter the amino acid residues that interact with either the HLA molecule or the T-cell receptor. Some amino acid modification in the anchor residues of peptides may result in enhanced binding to MHC class I and enhanced T-cell activation, whereas most other amino acid modifications will either have no effect or act to antagonize T-cell activation (25) (26) (27) (28) . Enhancement of T-cell activation by modifying HLA-anchor residues has been demonstrated for some human melanoma-associated antigens as well as for prostate-specific antigen (29 -31 ), but has not been demonstrated for most antigens associated with solid tumors, leukemias, or lymphomas.
The studies described here report the identification and characterization of a MUC-1 CTL epitope, not previously identified, in the non-VNTR extracellular region of MUC-1. These studies also describe the generation of an enhancer agonist entity of this epitope. Although the native CTL epitope was shown capable of generating human CTLs in vitro, the studies reported here demonstrate enhanced binding of the agonist epitope to the HLA-A2 molecule and enhanced stability of the peptide-MHC complex as compared with the native peptide. T-cell lines, generated from the same normal individuals with either the native or the agonist peptide, showed higher levels of lysis of target cells and enhanced IFN-␥ production when target cells were pulsed with the agonist versus the native peptide. Moreover, T-cell lines generated from two patients with pancreatic cancer using the agonist peptide showed higher levels of in vitro biological activity in terms of IFN-␥ production and lysis of tumor cells, as compared with T-cell lines generated in parallel from the same patients using the native epitope. These studies thus provide the rationale for the potential utility of the novel agonist epitope in peptide-and/or vector-mediated immunotherapy regimens for the treatment of MUC-1-expressing tumors.
MATERIALS AND METHODS

Cell Cultures
The human breast adenocarcinoma cell line MCF-7 (Ref. 32; HLA-A2 positive and MUC-1 positive), and SK-Mel-24 (HLA-A2 positive, MUC-1 negative) were purchased from American Type Culture Collection (Manassas, VA). The cultures were free of Mycoplasma and were maintained in complete medium [RPMI 1640 (Invitrogen Life Technologies, Inc., Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin (Invitrogen Life Technologies, Inc.)]. The C1R cell line is a human plasma leukemia cell line that does not express endogenous HLA-A or -B antigens (33) . C1R-A2 cells are C1R cells that express a transfected genomic clone of HLA-A2.1 (34) . These cells were obtained from Dr. William E. Biddison (National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD). The 174CEM-T2 cell line (T2) transport deletion mutant (35) was provided by Dr. Peter Cresswell (Yale University School of Medicine, New Haven, CT). C1R-A2 cells and T2 cells were Mycoplasma free and were maintained in RPMI 1640 complete medium and in Iscove's modified Dulbecco's complete medium (Invitrogen Life Technologies, Inc.), respectively.
Peptides
The amino acid sequence of MUC-1 was scanned for matches to consensus motifs for HLA-A2-binding peptides. We used the computer algorithm from the BioInformatics and Molecule Analysis Section of NIH (BIMAS) that was developed by Parker et al. (36) , which ranks potential MHC-binding peptides according to the predictive one-half-time dissociation of peptide/MHC complexes. The HLA-A2 allele was chosen because it is the most commonly expressed class I allele. Ten-mer peptides from the nonvariable number of tandem repeat sequence were synthesized if they conformed to the respective consensus motif. A panel of 10-mer MUC-1 peptides (Table 1) and analogs with single amino acid substitution to positions P1-to-P10 of P-92 MUC-1 peptide (Fig. 1) were made by American Peptide Company (Sunnyvale, CA) with purity Ͼ90%. In addition, a carcinoembryonic antigen (CEA) peptide CAP1-6D (28) Ͼ96% pure was made by American Peptide Company (Sunnyvale, CA).
Flow Cytometric Analysis
Single-Color Flow Cytometric Analysis. The method for single-color flow cytometric analysis has been described previously (37) . Briefly, cells were washed three times with cold Ca2ϩ-and Mg2ϩ-free Dulbecco's phosphate-buffered saline and then were stained for 1 h at 4°C using 1 g of the monoclonal antibody against HLA-A2 (A2, 28, One Lambda, Inc., Canoga Park, CA), CD3, CD4, CD8, or CD56 (BD Biosciences, San Jose, CA). MOPC-104E (IgM; Cappel/Organon Teknika Corp., West Chester, PA) was used as a negative control. The cells were then washed three times and incubated with a 1:100 dilution of FITC-labeled goat antimouse immunoglobulin (IgG; Kirkegaard and Perry Laboratories, Gaithersburg, MD). The cells were immediately analyzed using a Becton Dickinson FACScan equipped with a blue laser with an excitation of 15 mW at 488 nm. Data were gathered from 10,000 live cells, were stored, and were used to generate results.
Dual-Color Flow Cytometric Analysis. The procedure for dual-color flow cytometric analysis was similar to that for single-color analysis with the following exceptions. Anti-MHCclass II FITC/anti-CD11c phycoerythrin (PE), anti-MHC-class II FITC/anti-CD80 PE, anti-CD58 FITC/anti-CD54 PE, anti-MHC class I FITC/anti-MHC class II PE, and anti-IgG1 FITC/ anti-IgG2a PE (isotype controls) were used for the analysis of dendritic cells (DCs); Ͼ96% of the DCs were CD11c and MHC class II positive.
The antibodies used for the analysis of T-cell lines were anti-CD56 FITC/anti-CD8 PE, anti-CD4 FITC/anti-CD8 PE, and anti-CD45R0-FITC/anti-CD49d PE; Ͼ98% of the T-1191-P92 and T-1191-P-93L cells were CD8 positive. Antibodies to CD4, CD8, CD28, CD45RO, CD56, CD49d, CD54, CD80, CD86, CD58, and CD11c were purchased from BD Biosciences. Antibodies to MHC-class I and MHC-class II were purchased from Serotec, Oxford, United Kingdom. Staining was done simultaneously for 1 h, after which cells were washed three times, resuspended as above, and immediately analyzed using a Becton Dickinson FACScan equipped with a blue laser with an excitation of 15 mW at 488 nm with the use of the CELLQuest program.
Results were expressed in percentage of positive cells and mean fluorescence intensity. Mean fluorescence intensity was used to express the levels of fluorescence determined by measuring the average for all of the cells in the gated fluorescence dot plot. The mean fluorescence intensity value was collected in log scale on the FACScan.
Peptide Binding to HLA-A2
Binding of P-92 and P-92 analogs to HLA-A2 molecules was evaluated by the up-regulation of HLA-A2 expression on T2 cells as demonstrated by flow cytometry (38) . In this assay, increased stability (accumulation) of HLA-A2 molecules on the surface of T2 cells as a consequence of peptide binding is measured by increased binding of antibody directed against HLA-A2 molecule. Briefly, 1 ϫ 10 6 cells in serum-free Iscove's modified Dulbecco's complete medium were incubated with peptides at a concentration of 50 g/ml in 24-well culture plates at 37°C in 5% CO 2. Flow cytometry for peptide binding was performed using T2 cells and single-color analysis. After cells were washed three times in Dulbecco's phosphate-buffered saline, as described above, they were incubated for 1 h with a 1:100 dilution of anti-HLA-A2, 69-specific monoclonal antibody (One Lambda, Inc.) per 10 6 cells. UPC-10 (Cappel/Organon Teknika, West Chester, PA) was used as isotype control. The cells were then washed three times and incubated with 1:100 dilution of FITC-labeled antimouse IgG (BD Biosciences). Analysis was conducted with the FACScan, as described above. Cells were maintained on ice during all cell preparation and staining.
Culture of DCs from PBMCs
HLA-A2 normal donor peripheral blood mononuclear cells (PBMCs) were obtained from heparinized blood. PBMCs were separated using lymphocyte separation medium gradient (Organon Teknika, Durham, NC), as described previously (39) . DCs were prepared using a modification of the procedure described by Sallusto and Lanzavecchia (40) . PBMCs (1.5 ϫ 10 8 ) were resuspended in AIM-V medium containing 2 mM glutamine, 50 g/ml streptomycin, and 10 g/ml gentamicin (Invitrogen Life Technologies, Inc.) and were allowed to adhere to a T-150 flask (Corning Costar Corp., Cambridge, MA). After 2 h at 37°C, the nonadherent cells were removed with a gentle rinse. The adherent cells were cultured for 6 -7 days in AIM-V medium containing 100 ng/ml recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) and 20 ng/ml recombinant human interleukin (IL)-4. The culture medium was replenished every 3 days.
Recombinant Virus and Infection of DCs with Avipox Virus Containing MUC-1 (rF-MUC-1/TRICOM)
Recombinant fowlpox virus was constructed as described by Jenkins et al. (41) . A plaque-purified isolate from the POX-VAC-TC vaccine strain of fowlpox virus was used as the parental virus for this recombinant virus. The MUC-1, LFA-3, ICAM-1, and B7-1 sequences were inserted into the BamHIJ region of the fowlpox virus genome. In addition, the lacZ gene, under the control of the fowlpox C1 promoter, was included to identify and isolate recombinant viruses using a chromogenic assay for ␤-galactosidase. The MUC-1 gene that was inserted into fowlpox virus varies from the native MUC-1 (42) . It encodes a 30-amino-acid signal sequence, followed by the first 38 amino acids of the mature NH 2 -terminal sequence of the MUC-1 protein, 10 identical copies of the 20-amino acid repeated sequence, and the COOH-terminal portion of the protein.
The 600-bp repeated sequence was produced using overlapping synthetic oligonucleotides containing codons with numerous third-base variations in each repeat sequence without changing the encoded amino acids. This was done to minimize duplicated nucleotide sequences, which are unstable in pox viruses, while maintaining the repeated amino acid sequences.
rF-MUC-1/triad of costimulatory molecules (TRICOM) is a recombinant fowlpox virus that contains the MUC-1 gene under the control of the 40K promoter (43), the human LFA-3 gene under the control of the vaccinia 30K (M2L) promoter (44) , the human ICAM-1 gene under the control of the vaccinia I3 promoter (45) , and the human B7-1 gene under the control of the synthetic early/late (sE/L) promoter (46) . DCs (1 ϫ 10 6 ) were incubated in 1 ml of Opti-MEM medium (Life Technologies, Inc.) at 37°C with rF-MUC-1/TRICOM or control avipox virus vector [fowlpox wild-type (FP-WT)]. Titration experiments demonstrated that 4 ϫ 10 7 plaque-forming units/ml, equal to a multiplicity of infection of 40:1 for 2 h, were able to consistently induce transgene expression in approximately 35% of the infected DCs. DCs from different donors were used for the infection with rF-MUC-1/TRICOM with the range of efficiency of infection from 20 to 55%. The infected DCs were suspended in 10 ml of fresh, warm RPMI 1640 complete medium containing 100 ng/ml of recombinant human granulocyte macrophage colony-stimulating factor, 20 ng/ml recombinant human IL-4, and 20 ng/ml of TNF-␣ cultured for 24 h, and then subsequently used as antigen-presenting cells (APCs).
Generation of T-Cell Lines
Modification of the protocol described by Tsang et al. (47) was used to generate MUC-1-specific CTL. To generate T-cell lines T-1191-P-93L and T-1191-P-92, autologous DCs infected with rF-MUC-1/TRICOM were used as APCs. Autologous nonadherent cells were then added to APCs at an effector:APC ratio of 10:1. Cultures were then incubated for 3 days at 37°C in a humidified atmosphere containing 5% CO 2 . The cultures were then supplemented with recombinant human IL-2 at a concentration of 20 units/ml for 7 days; the IL-2 containing medium was replenished every 3 days. The 3-day incubation with pep-tide and 7-day IL-2 supplement constituted one in vitro stimulation (IVS) cycle. Primary cultures were restimulated with rF-MUC-1/TRICOM-infected autologous DCs, as described above, on day 11 to begin the next IVS cycle. rF-MUC-1/ TRICOM-infected autologous DCs were used as APCs for three IVS cycles. Irradiated (23,000 rads) autologous EBV-transformed B cells were used as APCs after the third IVS cycle. For the restimulation with EBV-transformed B cells, peptides at a concentration of 50 g/ml were used to pulse the autologous EBV-transformed B cells at a ratio of effector:APC of 1:3 for restimulation. Cultures were then incubated for 3 days at 37°C in a humidified atmosphere containing 5% CO 2 . After removal of the peptide-containing medium, the cultures were then supplemented with recombinant human IL-2 at a concentration of 20 units/ml for 7 days. T-cell lines from patients 18 and 23 (T-18-P-92, T-18-P93L, T-23-P-92, and T-23-P93L) were generated by stimulation of PBMCs with autologous DCs pulsed with the P-92 or P93L peptides using the same stimulation protocol as described above. The markers used for the analysis and identification of DCs were CD11c, MHC-class II, CD80, CD54, CD58, and CD83. CD3 was also used as a negative marker.
Cytotoxic Assay
Target cells (C1R-A2 or tumor cells) were labeled with 50 Ci of 111 In-labeled oxyquinoline (Medi-Physics Inc., Arlington, IL) for 15 min at room temperature. Target cells (0.3 ϫ 10 4 ) in 100 l of RPMI 1640 complete medium were added to each of 96 wells in flat-bottomed assay plates (Corning Costar Corp.). Labeled C1R-A2 target cells were incubated with peptides at the concentration indicated for 60 min at 37°C in 5% CO 2 before adding effector cells. No peptide was used when carcinoma cell lines were used as targets. Effector cells were suspended in 100 l of RPMI 1640 complete medium supplemented with 10% pooled human AB serum and added to the target cells. The plates were then incubated at 37°C in 5% CO 2 for 4 or 16 h. Supernatant was harvested for gamma counting with the use of harvester frames (Skatron, Inc., Sterling, VA).
Determinations were carried out in triplicate, and SDs were calculated. Specific lysis was calculated with the use of the following formula (all values in cpm): % lysis ϭ Observed release Ϫ spontaneous release Total release Ϫ spontaneous release ϫ 100
Spontaneous release was determined from wells to which 100 l of RPMI 1640 complete medium were added. Total releasable radioactivity was obtained after treatment of targets with 2.5% Triton X-100.
Detection of Cytokines
Supernatants of T cells exposed for 24 h to peptide-pulsed autologous EBV-transformed B cells, in IL-2-free medium at various peptide concentrations, were screened for secretion of IFN-␥ using an ELISA kit (R&D Systems, Minneapolis, MN). The results were expressed in pg/ml. A cytometric bead array (CBA) system (BD PharMingen, San Diego, CA) was also used to determine the secretion of multiple cytokines by specific T cells. The CBA system uses the fluorescence detection by flow cytometry to measure soluble analytes in a particles-based immunoassay. The BD PharMingen human Th1/Th2 cytokine CBA kit was used to measure IL-2, IL-4, IL-5, IL-10, and tumor necrosis factor ␣ protein levels in a single sample. The cytokine capture beads were mixed with PE-conjugated detection antibodies and then were incubated with recombinant cytokine standards or test samples to form sandwich complexes. The sample results were generated in graphic and tabular format, using BD PharMingen CBA analysis software. The results were expressed in pg/ml.
Statistical Analysis
Statistical analysis of differences between means was done using a two-tailed paired t test (Stat View statistical software, Abacus Concepts, Berkeley, CA). 
RESULTS
The primary amino acid sequence of human MUC-1 was analyzed for consensus motifs for novel HLA-A2 binding peptides. Twelve 10-mer peptides were identified, subsequently synthesized, and studied for binding to the HLA-A2 molecule in a T2 cell binding assay. The amino acid sequences and positions of these 10-mer peptides are shown in Table 1 . The CEA CAP1-6D peptide and a nonspecific cross-reacting antigen peptide were used as a positive and negative control, respectively. The predicted binding of the 12 peptides is also given in Table 1 . Three of these peptides (P-92, P-94, and P-1108) were shown to have the highest level of binding in the T2 assay.
Studies were then conducted to determine whether MUC-1-specific T-cell lines could be established from PBMCs of an apparently healthy donor. To accomplish this, autologous DCs infected with rF-MUC-1/TRICOM were used as APCs. rF-MUC-1/TRICOM is a replication-defective avipox vector containing the transgenes for MUC-1 and for a triad of human costimulatory molecules (B7-1, ICAM-1, and LFA-3, designated TRICOM). rF-MUC-1/TRICOM was shown to efficiently infect human DCs and hyperexpress each of the costimulatory molecules, as well as MUC-1, on the DC surface (Table 2) . Approximately 96% of the cells were CD11c and MHC-class II positive. The specificity of the MUC-1-specific T cells generated (designated T-1191-MUC-1) was analyzed after IVS cycle 3 (see "Materials and Methods") for their ability to release IFN-␥ after stimulation with autologous B cells pulsed with each of the MUC-1 peptides listed in Table 1 . The results shown in Table 3 demonstrate that when the T-1191-MUC-1 cells were stimulated with autologous B cells pulsed with peptides P-92, P-1135, P-94, P-1004, P-1069, and P-4, the T cells produced IFN-␥, whereas the use of autologous B cells pulsed with the other peptides did not result in IFN-␥ production. The results shown in Tables 1 and 3 demonstrate that the P-92 peptide had the highest level of T2 binding, as well as the ability to activate T-1191-MUC-1 cells to produce the highest levels of IFN-␥; this peptide was thus chosen for further study.
Analysis of the primary and secondary HLA-A2 anchor amino acid residues at positions 2 and 10 of the P-92 peptide revealed that modification of amino acids at these positions could potentially enhance the binding ability of the peptide to the HLA-A2 molecule. Thus, six different analogs of P-92 were synthesized, as shown in Table 4 , and were tested for their binding ability to T2 cells along with the native P-92 peptide. The CEA CAP-7 (HLA-A3 binding peptide), which has previously been shown not to bind to HLA-A2 (47), was used as a negative control. As shown in Table 4 , four of the six analog peptides bound to HLA-A2 at higher levels than the P-92 peptide. Analogs P-93L and P-93I bound HLA-A2 with the greatest efficiency. Experiments were then conducted to compare the ability of the P-93L and P-93I peptides to bind HLA-A2 at various peptide concentrations. As seen in Fig. 1 , the P-93L and P-93I peptides bound to HLA-A2 at higher levels than did P-92 at all peptide concentrations. The levels of binding were similar for P-93L and P-93I at the various peptide concentra- tions. These data thus indicated that both P-93L and P-93I with modification in the primary anchor position 2 (position 93 of the MUC-1 molecule) were potential agonists of peptide P-92.
Studies were then undertaken to examine the stability of the peptide-MHC complex for peptides P-92 (native), P-93L, and P-93I. Peptides were incubated with T2 cells overnight, the unbound peptides were washed off, and the cells were then incubated with Brefeldin A to block delivery of new class I molecules to the cell surface; at various time points cells were analyzed for the presence of peptide-HLA-A2 complexes. As shown in Fig. 2 , P-93L-HLA-A2, P-93M-HLA-A2, and P-93I-HLA-A2 complexes were more stable than P-92-HLA-A2 complexes over the 8-h observation period, with P-93L-HLA-A2 complexes slightly more stable than the P-93I-HLA-A2 and P-93M-HLA-A2 complexes over the same period of time. Thus, both the binding of peptides to MHC and the stability of the peptide-MHC complex were shown to be greater for the P-93L, P-93I, and P-93M peptides than the native P-92 peptide.
Studies were then conducted to compare the ability of the P-93L and P-93I agonist peptides, at various peptide concentrations, to activate the T-1191-MUC-1 cells. As seen in Fig. 3 , at each concentration of peptide, the pulsing of APCs with the P-93L peptide led to the greatest level of IFN-␥ production by T-1191-MUC-1 cells as compared with the P-93I peptide or the native P-92 peptide. The P-93L agonist peptide was thus chosen for further study. The cytokine profile of T-1191-MUC-1 cells stimulated with APCs, pulsed with either the P-92 or the P-93L peptide, was then analyzed. A CBA assay was used for the analysis. Table 5 shows the levels of each of the six cytokines produced by the T-1191-MUC-1 cell line stimulated with APCs pulsed with no peptide, P-92 peptide, and P-93L peptide. These results demonstrated greater production of type 1 cytokines IL-2 and IFN-␥ by T cells stimulated with the P-93L peptide than with the P-92 peptide. Low or undetectable levels of type 2 cytokines IL-4 and IL-10 were seen with either peptide. Tumor necrosis factor ␣ could not be detected in the supernatants at the 24-h time point.
To further compare the biological activity of the native P-92 peptide and the agonist P-93L peptide, two additional T-cell lines were established. This was accomplished, using as APCs, autologous DCs infected with rF-MUC-1/TRICOM and autologous PBMCs as effectors from an apparently healthy donor. After three IVSs, the T-cell lines were stimulated with autologous B cells pulsed with either the P-92 or the P-93L peptide. These two cell Fig. 1 Binding of MUC-1 peptide P-92 and the agonists P-93L and P-93I to HLA-A2 molecule. Peptides were analyzed for binding to the T2 cell line as described in "Materials and Methods." A, peptides were used at concentrations of 0 -50 g/ml. B, peptides were used at concentrations of 0 -12.5 g/ml. P-92 MUC-1 peptide (▫), P-93L (Ⅲ), P-93I ('). Results are expressed in mean fluorescence intensity (MFI). lines were designated T-1191-P-92 and T-1191-P-93L, respectively. The two cell lines were shown to be Ͼ98% CD8 positive, 99% CD49d positive, Ͻ2% CD56 positive, and Ͼ75% CD45RO positive cells. The two T-cell lines were then analyzed for their ability to lyse peptide-pulsed targets. T-1191-P-93L was shown to lyse C1R-A2 cells pulsed with P-93L peptide to a greater extent than cells pulsed with the P-92 peptide (Fig. 4, squares) . T-1191-P-92 also lysed target cells pulsed with the P-93L peptide to a greater extent than those pulsed with the P-92 peptide (Fig. 4,  triangles) . The data in Fig. 4 also show that when target cells are pulsed with the native peptide, the T-cell line established with the agonist P-93L peptide lyses target cells at greater levels than the T-cell line established with the native peptide. This was seen at two different E:T ratios. T-1191-P-93L cells and T-1191-P-92 cells did not lyse C1R-A2 cells when pulsed with control CEA CAP1-6D peptide (Fig. 4, circles) . Studies were then conducted to determine whether these two T-cell lines could lyse the MUC-1-positive and HLA-A2-positive breast carcinoma cell line MCF-7. The MUC-1-negative HLA-A2-positive SK-Mel-24 melanoma cell line was used as a negative control. As shown in Table 6 , MCF-7 cells were lysed by both the T-1191-P-92 and the T-1191-P-93L cells. No lysis was observed against the SK-Mel-24 cells. T-1191-P-93L cells were shown to lyse MCF-7 cells to a greater degree as compared with the T-1191-P-92 cell line. The addition of unlabeled C1R-A2 cells pulsed with the P-92 peptide and P-93L peptide, but not with the CEA CAP1-6D control peptide, decreased the cytotoxic activity of both T-cell lines, demonstrating the MUC-1 specificity of the lysis ( Table 6 ). The cytotoxic activity of these T-cell lines against MCF-7 cells was also shown to be HLA-A2 restricted, as demonstrated by the inhibition of lysis with the addition of anti-HLA-A2, 69 antibody, but not with the control antibody UPC-10 ( Table 7) .
The T-1991-P-92 and T-1191-P-93L T-cell lines were derived from an apparently healthy individual. Studies were then conducted to determine whether additional T-cell lines could be established from two patients with pancreatic cancer (patients 23 and 18). Four MUC-1-specific T-cell lines were generated and were designated T-23-P-92, T-23-P-93L, T-18-P-92, and T-18-P-93L. The T-cell lines T-18-P-92 and T-18-P-93L were generated from patient 18 by stimulation of PBMCs with autologous DCs pulsed with the P-92 and P-93L peptides, respectively. T-cell lines T-23-P-92 and T-23-P-93L were generated from patient 23 by stimulation of PBMCs by autologous DCs pulsed with the P-92 and P-93L peptides, respectively. As seen Fig. 3 Ability of autologous B cells pulsed with native MUC-1 peptide P-92 (Ⅺ), P-93L peptide (f), and P-93I peptide (OE) to induce IFN-␥ production by MUC-1-specific T cells. Peptides were used at concentrations of 0 -6.25 g/ml. Results are expressed in pg/ml. Fig. 4 Cytotoxicity of the MUC-1-specific T-cell lines against C1R-A2 cells pulsed with P-92 and P-93L peptide. T-1191-P-93L against C1R-A2 pulsed with P-93L peptide (Ⅲ), T-1191-P-93L against C1R-A2 pulsed with P-92 peptide (▫), T-1191-P-93L against C1R-A2 pulsed with CAP1-6D peptide (•), T-1191-P-92 against C1R-A2 pulsed with P-93L peptide ('), T-1191-P-92 against C1R-A2 pulsed with P-92 peptide (), T-1191-P-92 against C1R-A2 pulsed with CAP1-6D peptide (⅙). E:T ratio ϭ 25:1 and 12.5:1 in a 16-h 111 In release assay. Bars, SD. Table 5 Cytometric bead array assay for the production of cytokines by MUC-1 peptide-stimulated T cells The production of interleukin (IL)-2, IL-4, IL-5, IL-10, tumor necrosis factor (TNF)-␣, and IFN-␥ was analyzed. Standards at concentrations of each cytokine at 0 pg/ml, 312 pg/ml, and 5000 pg/ml were used to determine the concentrations of these six cytokines in the samples. T-1191 MUC-1 cells at in vitro stimulation (IVS)-3 were used as effectors. T cells were stimulated with irradiated autologous EBVtransformed B cells pulsed without peptide or with P-92 or P-93L peptides at a concentration of 25 g/ml, and an effector:antigenpresenting cell ratio of 1:3. Twenty-four-h culture supernatants were collected and screened for the secretion of cytokines. Results are expressed in pg/ml/10 6 cell/ml.
P-92 58.8 Ͻ20 Ͻ20 Ͻ20 Ͻ20 266 P-93L 366.9 Ͻ20 140.9 Ͻ20 Ͻ20 650
in Table 8 , all four T-cell lines from both pancreatic cancer patients could be stimulated to produce IFN-␥ when stimulated with DCs pulsed with either the P-92 or the P-93L peptide. No IFN-␥ production was observed, however, when these T cells were stimulated in a similar manner with the CEA peptide CAP1-6D. For all four T-cell lines, greater levels of IFN-␥ production were seen when the P-93L agonist peptide was used as compared with the P-92 native peptide. It also should be noted that the T-cell lines derived using the agonist peptide always showed higher levels of stimulation than did the T-cell lines derived from the native peptide, when a given peptide was used for stimulation. Studies were then conducted to determine whether the T-cell lines derived from cancer patient 23 could lyse MUC-1-positive HLA-A2-positive cancer cells. The SKMel-24 cell line (MUC-1 negative and HLA-A2 positive) was used as a negative control for specificity. As can be seen in Tables 9 and 10 , the T-23-P-93L line, T-23-P-92 line, T-18-P-93L line, and T-18-P-92 line showed lysis of the MCF-7 carcinoma cells at two different E:T ratios, but showed no lysis of the melanoma cell line. In concordance with the results shown above, the T-cell line (T-23-P-93L, T-18-P-93L), derived using the agonist peptide, demonstrated greater lysis of the tumor cells than the T-cell line (T-23-P-92, T-18-P-92) derived using the native peptide. This was seen at two different E:T ratios.
DISCUSSION
This study identifies a MUC-1-derived HLA-A2-restricted CTL epitope (P-92) that maps outside the VNTR region. Human T-cell lines established with the P-92 peptide were shown to lyse peptide-pulsed targets and MCF-7 carcinoma cells in a MHC-restricted manner. The addition of the unlabeled P-92-pulsed C1R-A2 cells was shown to eliminate the CTL activity against MCF-7 cells. These results collectively indicate that the P-92 peptide represents a naturally processed CTL epitope. In the studies reported here, we have also modified the primary anchor residues of the P-92 peptide to enhance the binding Table 6 Ability of MUC-1-specific T-cell lines T-1191-P-92 and T-1191-P-93L to lyse a MUC-1-expressing tumor cell line (MCF- 7) Results are expressed in percentages of specific lysis at E:T ϭ 25:1. The numbers in parentheses are the SD. MCF-7 (human breast carcinoma cell line) cells are MUC-1 positive and HLA-A2 positive. SK-Mel-24 (melanoma) cells are MUC-1 negative and HLA-A2 positive. T-1191-P-92 cells and T-1191-P-93L cells were used at in vitro stimulation (IVS)-5. The T-1191-P-92 cell line was passaged on the native P-92 peptide, and the T-1191-P-93L cell line was passaged on the agonist P-93L peptide, from IVS-3 to IVS-5. MCF-7 cells were labeled with 111 In-labeled MCF-7 cells, and unlabeled C1R-A2 cells were used at a ratio of 1:10. C1R-A2 cells were incubated with or without P-92 peptide (25 g/ml), P-93L peptide (25 g/ml), or CAP1-6D control peptide (25 g/ml).
Target
T-1191-P-92 T-1191-P-93L a Statistically significant lysis (P Ͻ 0.01, two-tailed t test) when comparing lysis of MCF-7 cells versus SK-Mel-24 cells. There is also a statistical significance (P Ͻ 0.01, two-tailed t test) when comparing lysis of MCF-7 ϩ C1R-A2 versus MCF-7 ϩ C1R-A2 ϩ P-92 peptide or MCF-7 ϩ C1R-A2 versus MCF-7 ϩ C1R-A2 ϩ P-93L. Table 7 Anti-HLA-A2 antibody inhibition of MCF-7 cell lysis by T-cell lines MCF-7 cells (1 ϫ 10 7 ) were labeled with 111 In and were incubated for 1 h in the presence of medium containing no antibody, anti-HLA-A2, 69 (1:100, 1:1000 dilution), or UPC-10 (10 g/ml). Cells were then used as targets in an 18-h cytotoxic assay. The results are expressed in percentage of specific lysis at E:T ratios of 12.5:1. The numbers in parentheses are the SD.
Antibody
T-1191-P-93L T-1191-P-92 a Statistically significant lysis (P Ͻ 0.01, two-tailed t test) when comparing percentage of lysis of none versus the percentage of lysis with anti-HLA-A2, 69. UPC-10 is a control antibody. Table 8 Production of IFN-␥ by T-cell lines generated from two pancreatic cancer patients stimulated with P-92 and agonist P-93L peptide Cells from four MUC-1-specific T-cell lines established from two pancreatic cancer patients (patients 23 and 18) were used as effector cells at in vitro stimulation (IVS)-4. These T-cell lines were established by stimulation with P-92-pulsed autologous dendritic cells (DCs; T-23-P-92 and P-18-P-92) or P-93L pulsed autologous DCs (T-23-P-93L and T-18-P-93L). For IFN-␥ production, T-cell lines were stimulated with irradiated HLA-A-positive allogeneic DCs pulsed with either P-92 or P-93L peptide at a concentration of 25 g/ml and an effector-to-antigenpresenting cell ratio of 10:1. Twenty-four-h culture supernatants were collected and screened for the secretion of IFN-␥. Results are expressed as pg IFN-␥ produced.
T-cell line Peptide P-92 P-93L CAP1-6D Table 9 Ability of T-cell lines from a pancreatic cancer patient, generated with agonist peptide P-93L, to lyse cancer cells expressing native MUC-1 affinity of the peptide to the HLA-A2 molecule. Six analogs were analyzed, and one of them, designated P-93L, was shown to be superior to the native P-92 epitope in terms of the affinity of binding to the MHC molecule, the avidity of the peptide-MHC complex, and the ability to activate CTL in vitro.
It has been demonstrated that residues strongly associated with good binding of 10-mer peptides to HLA-A2. Other MUC-1-derived HLA-A0201-restricted CTL 9-mer epitopes from the non-VNTR region have been reported. Three 9-mer peptides, MUC 79 -87 (TLAPATEPA), MUC [167] [168] [169] [170] [171] [172] [173] [174] [175] (ALGSTAPPV), and MUC 264 -272 (FLSFHISNL; Ref. 24) , were analyzed in HLA-A2/K b -transgenic mice and were shown to elicit peptide-specific CTLs and to protect mice against challenge with a MUC-1-positive A2K b -expressing murine tumor. Another peptide, MUC [13] [14] [15] [16] [17] [18] [19] [20] [21] (LLLTVLTVV), was found to bind well to the HLA-A2 molecule but did not display immunogenicity in vivo (23) . Peptide MUC 353-361 (NLTISDVSV), which was found to be immunogenic in HLA-A2.1/D b -␤2 microglobulin single-chain transgenic mice, was a poor binder to HLA-A2 molecule (23, 24) . Two MUC-1-specific epitopes, designated M1.1 and M1.2, were previously shown to lyse both peptidepulsed targets and human carcinoma cells expressing MUC-1 (21) . Autologous DCs pulsed with these peptides were used to vaccinate patients with metastatic breast cancer and ovarian cancer. CTL responses from vaccinated patients were demonstrated principally to the M1.2 peptide (51); it is interesting to note that in addition to the generation of T cells reactive with the MUC-1-derived peptide, T cells specific for CEA and MAGE-3 were also detected after multiple vaccinations. We have demonstrated that production of lymphotactin by a MUC-1-specific T-cell line occurs when the line is stimulated with autologous B cells pulsed with the P-93L peptide but not with the native P-92 peptide (52) . Enhanced expression of lymphotactin by CD8ϩ CEA-specific T cells has also been reported when a CEA agonist peptide (CAP1-6D) was used for the stimulation (53) . A clinical trial using DC pulsed with the agonist CAP1-6D peptide has demonstrated clinical responses in patients with CEA-expressing carcinomas (54) , whereas in another Phase 1 clinical trial using DCs pulsed with native CAP-1 peptide, only modest CAP-1-specific responses were observed (55) . On the basis of these clinical responses, together with the results from the CEA agonist peptide study and the ability of lymphotactin to mainly recruit activated T cells, it is conceivable that the enhanced specific antitumor immune responses observed with the agonist CAP1-6D peptide may be due in part to the increased lymphotactin production.
Several other clinical trials involving MUC-1-based vaccines have been reported. These vaccines consisted of a synthetic 105-mer MUC-1 peptide that has five repeated immunodominant epitopes, MUC-1-cDNA-transfected DCs, recombinant vaccinia virus encoding MUC-1 and IL-2, STn-KLH [Theratope(R)], and a recombinant vaccinia virus containing MUC-1 (56 -60). These vaccine trials were shown to be safe, with some evidence of antitumor activity.
The P-93L epitope, moreover, is the first agonist epitope to be described for MUC-1. The MUC-1 agonist epitope can potentially be used as a peptide vaccine in adjuvant, in autologous peptide-pulsed DC therapy, or as part of a recombinant viral or bacterial vector. This investigation also provides evidence for the concept that the alteration of a single residue in the CTL peptide epitope of a relatively weakly immunogenic "selfantigen" can be used to activate specific T cells more efficiently than the native antigen. a Statistical significance (P Ͻ 0.01, two-tailed t test) when comparing lysis of MCF-7 cells versus SK-Mel-24 cells by T-18-P-93L and T-18-P-92 cells.
b Statistical significance (P Ͻ 0.01, two-tailed t test) when comparing lysis of MCF-7 cells by T-18-P-93L and T-18-P-92 cells.
